Quantification of adeno-associated virus particles and empty capsids by optical density measurement

被引:177
作者
Sommer, JM [1 ]
Smith, PH [1 ]
Parthasarathy, S [1 ]
Isaacs, J [1 ]
Vijay, S [1 ]
Kieran, J [1 ]
Powell, SK [1 ]
McClelland, A [1 ]
Wright, JF [1 ]
机构
[1] Avigen Inc, Alameda, CA 94502 USA
关键词
adeno-associated virus; spectrophotometry; extinction coefficient; real-time quantitative PCR; capsid ELISA;
D O I
10.1016/S1525-0016(02)00019-9
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We show here that UV absorbance of denatured adeno-associated virus (AAV) vector provides a simple, rapid, and direct method for quantifying vector genomes and capsid proteins in solution. We determined the molar extinction coefficients of capsid protein to be 3.72 x 10(6) M-1 cm(-1) at 260 nm and 6.61 x 10(6) M-1 cm(-1) at 280 nm. For recombinant AAV vectors, extinction coefficients can be calculated by including the predicted absorbance of the vector DNA. Since the amount of empty capsids in purified vector preparations lowers the A(260)/A(280) ratio in a predictable manner, the vector genome (vg) and capsid particle (cp) titers in purified AAV vector preparations can be calculated from the absorbance at 260 nm and the A(260)/A(280) ratio. To validate this method, the vg and cp titers calculated by UV absorbance were compared with titers determined by quantitative (Q)-PCR and capsid ELISA. The vg titers determined by absorbance agreed well with titers determined by Q-PCR. The cp/vg ratio determined by the A(260)/A(280) method also correlated well with those determined by AAV capsid ELISA in conjunction with Q-PCR. This new method provides a simple and rapid means to determine AAV vg titers and the ratio of empty to full particles in purified virus preparations.
引用
收藏
页码:122 / 128
页数:7
相关论文
共 23 条
  • [1] ANDERS J, 2001, BIOPHARM GUIDE BIOAN
  • [2] BERNS KI, 1996, FIELDS VIROLOGY, P2173
  • [3] Cantor C. R, 1980, TECHNIQUES STUDY BIO
  • [4] Clark KR, 2002, KIDNEY INT, V61, P9
  • [5] Development of formulations that enhance physical stability of viral vectors for gene therapy
    Croyle, MA
    Cheng, X
    Wilson, JM
    [J]. GENE THERAPY, 2001, 8 (17) : 1281 - 1290
  • [6] Drittanti L, 2001, J GENE MED, V3, P59, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM152>3.0.CO
  • [7] 2-U
  • [8] Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo
    Gao, GP
    Qu, G
    Burnham, MS
    Huang, J
    Chirmule, N
    Joshi, B
    Yu, QC
    Marsh, JA
    Conceicao, CM
    Wilson, JM
    [J]. HUMAN GENE THERAPY, 2000, 11 (15) : 2079 - 2091
  • [9] CALCULATION OF PROTEIN EXTINCTION COEFFICIENTS FROM AMINO-ACID SEQUENCE DATA
    GILL, SC
    VONHIPPEL, PH
    [J]. ANALYTICAL BIOCHEMISTRY, 1989, 182 (02) : 319 - 326
  • [10] Progress in adeno-associated virus type 2 vector production: Promises and prospects for clinical use
    Grimm, D
    Kleinschmidt, JA
    [J]. HUMAN GENE THERAPY, 1999, 10 (15) : 2445 - 2450